Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer:

M. Di Maio; G. Daniele; M.C. Piccirillo

Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer

Authors

M. Di Maio Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
G. Daniele Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.
M.C. Piccirillo Clinical Trials Unit, Istituto Nazionale Tumori IRCCS – “Fondazione G. Pascale”, Napoli, Italy.

Abstract

No abstract available

Downloads

Published

2013-10-15

How to Cite

Di Maio M, Daniele G, Piccirillo M. Impact on health-related quality of life of the addition of bevacizumab to first-line chemotherapy for ovarian cancer: . CBN [Internet]. 2013 Oct. 15 [cited 2024 Dec. 4];1(1):33-5. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/254

Download Citation

Issue

Vol. 1 No. 1 (2013): January - December 2013

Section

Methodological corner

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.